Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Shares in French peanut allergy specialist DBV Technologies were boosted 20% in pre-market trading on Thursday, after the firm announced positive topline results from the Phase III PEPITES trial. 9 January 2020
Biotechnology
The US regulator has added another approval to the list for Merck & Co’s Keytruda (pembrolizumab), as monotherapy for certain people with non-muscle invasive bladder cancer (NMIBC). 9 January 2020
Biotechnology
Altavant Sciences has entered into a definitive agreement to acquire USA-based Onspira Therapeutics, a private drug development company similarly focused on therapeutics for rare pulmonary diseases. 9 January 2020
Biotechnology
US biopharma Immunic has opted to exercise an exclusive global option to license a group of compounds, designated as IMU-856, from Daiichi Sankyo. 8 January 2020
Biotechnology
Sweden-based CNS specialist AlzeCure Pharma has appointed Martin Jönsson as its new chief executive with effect on January 9. 8 January 2020
Biotechnology
Japanese drugmaker Kyowa Kirin today said that it has submitted a supplemental application for Lumicef (brodalumab) for the treatment of axial spondyloarthritis (axSpA) in Japan. 8 January 2020
Biotechnology
UK-based Avacta Group and Korean pharma Daewoong Pharmaceutical are to form a joint venture (JV) aimed at developing cell and gene therapies incorporating the Cambridge-based company’s Affimer proteins. 8 January 2020
Biotechnology
A new collaboration between Aragen Bioscience and Serum Institute of India will see the development of multiple stable cell lines in support of the latter’s HIV program. 8 January 2020
Biotechnology
Spain’s largest drugmaker could be about to get bigger with the news that Almirall has entered into an option agreement to buy Bioniz Therapeutics to further expand its pipeline in dermatology. 8 January 2020
Biotechnology
Chinese biopharma Innovent Biologics has teamed up with RNAi specialist Sirnaomics to combine their therapies in cancer trials. 8 January 2020
Biotechnology
Clinical-stage US biopharma company SAB Biotherapeutics has entered into multiple collaboration and option agreements with CSL Behring. 8 January 2020
Biotechnology
Emerging US biotech Tyme Technologies saw its shares leap 13.6% to $1.75 in unusually heavy volume, on news of a potential $40 million deal with Eagle Pharmaceuticals focused on the co-promotion of Tyme's lead CMBT candidate oral SM-88 in advanced cancers. 8 January 2020
Biotechnology
Adding to the list of marketing clearances for the drug, now Health Canada has approved Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (MTX). 7 January 2020
Biotechnology
Shares of US biotech Protagonist Therapeutics gained more than 4% to $6.96 by mid-morning, after it revealed a milestone payment under its 2017 collaboration with Johnson & Johnson unit Janssen Biotech. 7 January 2020
Biotechnology
Velabs Therapeutics and fellow German firm Alytas Therapeutics have agreed a licensing deal for the development and commercialization of certain of the latter’s antibodies. 7 January 2020
Biotechnology
US biopharma Apellis Pharmaceuticals opened Tuesday’s trading 30% higher. 7 January 2020
Biotechnology
The former executive team of Swiss biotech Therachon has founded a new company, VectivBio, with $35 million in financing to target serious rare diseases. 7 January 2020
Biotechnology
CNS specialist AlzeCure Pharma has exclusively in-licensed a vanilloid receptor subtype 1 (VR1) project targeting neuropathic pain from fellow Swedish company Acturum Life. 7 January 2020
Biotechnology
US biotech firm FibroGen has appointed Enrique Conterno as the company’s chief executive and a member of the board of directors, effective immediately. 7 January 2020
Biotechnology
Keytruda (pembrolizumab) is already approved in five lung cancer indications, but the Merck & Co drug does not have the market entirely cornered, new data shows. 7 January 2020
All news
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze